Kisqali, Ribociclib, is used to treat postmenopausal women with locally advanced or metastatic breast cancer, that is HR positive and HER2 negative, in combination with a non-steroidal aromatase inhibitor, as initial endocrine based-therapy.
Therapeutic group: Cyclin-dependent kinase enzyme inhibitors. Kisqali contains the active ingredient ribociclib, which belongs to a group of medicines called cyclin-dependent kinase (CDK) inhibitors. Kisqali works by blocking proteins called cyclin-dependent kinases 4 and 6, which are important for the growth and division of cells. Blocking these proteins can slow down the growth of cancer cells and delay the progression of the cancer.
To Read More>>